- Home
- AXR vs HURA Comparison
AXR vs HURA Comparison
Compare AXR & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXR
- HURA
- Stock Information
- Founded
- AXR 1961
- HURA 2009
- Country
- AXR United States
- HURA United States
- Employees
- AXR N/A
- HURA N/A
- Industry
- AXR Homebuilding
- HURA
- Sector
- AXR Real Estate
- HURA
- Exchange
- AXR Nasdaq
- HURA Nasdaq
- Market Cap
- AXR 114.8M
- HURA 103.3M
- IPO Year
- AXR N/A
- HURA N/A
- Fundamental
- Price
- AXR $23.62
- HURA $2.34
- Analyst Decision
- AXR
- HURA Strong Buy
- Analyst Count
- AXR 0
- HURA 2
- Target Price
- AXR N/A
- HURA $11.50
- AVG Volume (30 Days)
- AXR 14.9K
- HURA 476.4K
- Earning Date
- AXR 07-22-2025
- HURA 08-15-2025
- Dividend Yield
- AXR N/A
- HURA N/A
- EPS Growth
- AXR 472.07
- HURA N/A
- EPS
- AXR 2.41
- HURA N/A
- Revenue
- AXR $58,052,000.00
- HURA N/A
- Revenue This Year
- AXR $120,108.69
- HURA N/A
- Revenue Next Year
- AXR $8.16
- HURA $69.15
- P/E Ratio
- AXR $9.87
- HURA N/A
- Revenue Growth
- AXR 30.35
- HURA N/A
- 52 Week Low
- AXR $17.60
- HURA $1.80
- 52 Week High
- AXR $39.68
- HURA $10.49
- Technical
- Relative Strength Index (RSI)
- AXR 67.84
- HURA N/A
- Support Level
- AXR $20.85
- HURA N/A
- Resistance Level
- AXR $24.21
- HURA N/A
- Average True Range (ATR)
- AXR 1.15
- HURA 0.00
- MACD
- AXR 0.29
- HURA 0.00
- Stochastic Oscillator
- AXR 72.99
- HURA 0.00
About AXR AMREP Corporation
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.